Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective faithfully but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last few shares. The first CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set away all of the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly marketing image in the Uptick Newswire job interview that I came away with a poor impression of the company.

Irony of irony, the poor opinion of mine of the company has grown steadily, yet the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of this expertise and also connected intellectual property coming from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) as well as the very first brand new drug application approval ($five million), and also royalty payments of five % of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and many indications, it’s this individual treatment and a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple disease types, multiple delivering presentations in addition to multiple publications.

Might all this be smoke and mirrors? That’s a question I’ve been asking myself from the really start of the interest of mine in this particular organization. Judging with the multiples of thousands of several comments on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a classic battleground, or possibly some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *